{"filing":{"accession_number":"0001193125-26-288468","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"fblg-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526288468/fblg-20260625.htm"},"events":[{"id":14645,"run_id":13047,"accession_number":"0001193125-26-288468","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"FibroBiologics completed a private placement on June 25, 2026, raising approximately $3.0 million in gross proceeds through the issuance of 4,081,633 shares of common stock (or pre-funded warrants) and series A and B warrants exercisable for up to 8,163,266 additional shares, with potential for up to $6.0 million in additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions and have not been registered under the Securities Act, creating significant dilution to existing shareholders.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12129,"accession_number":"0001193125-26-288468","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"FibroBiologics entered into a Securities Purchase Agreement on June 25, 2026, for a private placement raising $3.0 million in gross proceeds through the issuance of pre-funded warrants, short-term warrants, and long-term warrants to purchase up to 12.2 million shares of common stock (4,081,633 shares × 3 tranches). This is a classic dilutive private placement of unregistered equity securities under Section 4(a)(2) and Regulation D, with significant potential dilution to existing shareholders. The filing explicitly notes the securities were sold in a private placement exempt from registration, and the company plans to file a resale registration statement, confirming the dilutive nature of the issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12130,"accession_number":"0001193125-26-288468","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"FibroBiologics disclosed an unregistered private placement of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof) plus series A and B warrants exercisable for up to 8,163,266 additional shares, totaling approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the company is a clinical-stage biotech with limited liquidity, making this capital raise material to investors assessing the registrant's financial position and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12131,"accession_number":"0001193125-26-288468","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"FibroBiologics announced and closed a private placement of 4,081,633 shares of common stock (or pre-funded warrants) plus series A and B warrants, raising approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, characteristic of a dilutive private placement. The filing explicitly discloses the offering was \"priced at-the-market under Nasdaq rules\" and notes the securities have not been registered under the Securities Act, confirming this is a private placement capital raise typical of small-cap biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12129,"accession_number":"0001193125-26-288468","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"FibroBiologics entered into a Securities Purchase Agreement on June 25, 2026, for a private placement raising $3.0 million in gross proceeds through the issuance of pre-funded warrants, short-term warrants, and long-term warrants to purchase up to 12.2 million shares of common stock (4,081,633 shares × 3 tranches). This is a classic dilutive private placement of unregistered equity securities under Section 4(a)(2) and Regulation D, with significant potential dilution to existing shareholders. The filing explicitly notes the securities were sold in a private placement exempt from registration, and the company plans to file a resale registration statement, confirming the dilutive nature of the issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-29"},{"id":12130,"accession_number":"0001193125-26-288468","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"FibroBiologics disclosed an unregistered private placement of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof) plus series A and B warrants exercisable for up to 8,163,266 additional shares, totaling approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the company is a clinical-stage biotech with limited liquidity, making this capital raise material to investors assessing the registrant's financial position and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-29"},{"id":12131,"accession_number":"0001193125-26-288468","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"FibroBiologics announced and closed a private placement of 4,081,633 shares of common stock (or pre-funded warrants) plus series A and B warrants, raising approximately $3.0 million upfront with up to $6.0 million in potential additional proceeds. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, characteristic of a dilutive private placement. The filing explicitly discloses the offering was \"priced at-the-market under Nasdaq rules\" and notes the securities have not been registered under the Securities Act, confirming this is a private placement capital raise typical of small-cap biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:16:49.992096+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-06-29"}]}